Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.

LW-1017, an oral drug that switches the brain’s cleanup system back on, reduced Parkinson’s and Alzheimer’s pathology in aged ...

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.

Resolution Therapeutics has treated its last EMERALD trial patient, putting macrophage-based therapy on track for results ...

Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...

What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells? Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver ...

Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...

LOY-003, a daily tablet for large and giant breeds, has earned RXE acceptance, the third such milestone for a Loyal lifespan ...

Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...

Seoul biotech’s redesigned method makes circular RNA up to seven times more efficient to build, widening what RNA medicine can treat.